Evans Scientific Report 2012 (50.99 kB)

Key Publications

Olmos D, A’Hern R, Marsoni S, Tabernero J, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JHM, Gianni L, Brunetto AT, Evans TRJ, Wilson R, Sessa C, Plummer RE, Morales R, Soria J-C, Kaye SB, on behalf of the European Drug Development Network (EDDN). Patient selection for oncology Phase I trials – a multi-institutional study of prognostic factors. Journal of Clinical Oncology 30: 996-1004, 2012

Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, Frame MC, Evans TRJ, Sansom OJ. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 107: 246-251, 2010

Morton JP, Karim SA, Graham K, Timpson P, Jamieson NB, Athineos D, McKay CJ, Heung M-Y, Oien KA, Frame MC, Evans TRJ, Sansom OJ, Brunton VG. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 139: 292-303, 2010

Education and qualifications
2000: FRCP (London)
1998: FRCP (Glasgow)
1993: MD, University of London
1988: MRCP (UK)
1984: MB BS, St Bartholomew’s Hospital, University of London

Appointments
2005-present: Professor of Translational Cancer Research (University of Glasgow); Honorary Consultant Medical Oncology (Beatson West of Scotland Cancer Centre, Glasgow)
2007-2010: Deputy Head, Division of Cancer Sciences & Molecular Pathology, University of Glasgow
2007-present: Honorary Group Leader, Beatson Institute for Cancer Research
2010-present: Head, Experimental Cancer Therapeutics Unit, University of Glasgow
2011-present: Lead, Glasgow Experimental Cancer Medicine Centre (ECMC)
2012-present: Director, Institute of Cancer Sciences, University of Glasgow (Acting Director from November 2011)
1996-2005: Senior Lecturer and Honorary Consultant in Medical Oncology, Centre for Oncology & Applied Pharmacology, University of Glasgow; Beatson Oncology Centre, Glasgow
1991-1996: Lecturer/Honorary Senior Registrar in Medical Oncology, St George’s Hospital Medical School, London
1989-1991: Research Fellow in Medical Oncology, St George’s Hospital Medical School and Charing Cross Hospital Medical School, University of London; Institute of Cancer Research, Sutton, Surrey

Committee membership
2013: Steering Committee, Astra Zeneca-ECMC Combination Studies Alliance
2012-2013: All Ireland Cooperative Oncology Group (ICORG) Panel of international peer reviewers
2011-present: Glasgow Biomedicine Board
2010-present: Chairman, Wales Clinical Trials Unit Independent Data Monitoring Committee (Phase II trials)
2007-present: NCRI Upper GI Cancer Clinical Studies Group (Pancreatic Cancer sub-group from 2013)
2007-present: CRUK New Agents Committee
2006-present: Chairman, Steering Committee, Analytical Services Unit, University of Glasgow
2006-present: Scholarship Committee, The Royal College of Surgeons and Physicians of Glasgow (Chairman from 2012)
2005-present: Editorial Board, British Journal of Cancer (Co-Editor - Clinical Subjects from 2013)
2004-present: Faculty 1000 Oncology Evaluation Board – Oncology Agents Section
2004-present: Scottish Cancer Research Network (West of Scotland) Steering Committee
2000-present: EORTC Gastro-Intestinal Tract Clinical Trials Group

2013
Macpherson IRJ, Poondru S, Simon GR, Gedrich R, Brock K, Hopkins CA, Stewart K, Stephens A, Evans TRJ. A Phase 1, Pharmacokinetic, Pharmacodynamic, and Dose Escalation Study of OSI-930 and Erlotinib in Patients with Advanced Solid Tumors. European Journal of Cancer 49: 782-789, 2013

Lassen U, Miller WH Jr, Hotte S, Evans TRJ, Kollmansberger C, Adamson D, Nielsen DL, Spicer J, Chen E, Meyer T, Brown K, Rafi R, Sawyer MB. Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours. Cancer Chemotherapy & Pharmacology 71: 543-549, 2013

Steele CW, Jamieson NB, Evans TRJ, McKay CJ, Sansom OJ, Morton JP, Carter CR. Exploiting inflammation for therapeutic gain in pancreatic cancer. British Journal of Cancer, 2013 in press

Karim SA, Creedon H, Patel H, Carragher NO, Morton JP, Muller WJ, Evans TRJ, Gusterson B, OJ Sansom OJ, Brunton VG. Dasatinib inhibits mammary tumour development in a genetically engineered mouse model. Journal of Pathology, 2013 in press

2012
Anthoney DA, Naik J, MacPherson IRJ, Crawford D, Hartley JM, Hartley JA, Saito T, Abe M, Jones K, Miwa M, Twelves CJ, Evans TRJ. Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer 12: 536-46, 2012

Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O’Brien JP, Schellens JH, Evans TR. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 106: 1598-604, 2012

Jamieson NB, Morran DC, Morton JP, Ali A, Dickson EJ, Carter CR, Sansom OJ, Evans TR, McKay CJ, Oien KA. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res 18: 534-45, 2012

Macpherson IR, Poondru S, Simon GR, Gedrich R, Brock K, Hopkins CA, Stewart K, Stephens A, Evans TR. A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours. Eur J Cancer doi: 10.1016/j.ejca.2012.09.036, published online 22 Oct 2012

Olmos D, A’Hern R P, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schoffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB. Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. J Clin Oncol 30: 996-1004, 2012

Salazar R, Jones RJ, Oaknin A, Crawford D, Cuadra C, Hopkins C, Gil M, Coronado C, Soto-Matos A, Cullell-Young M, Iglesias Dios JL, Evans TR. A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. Cancer Chemother Pharmacol 70: 673-81, 2012

Cairney CJ, Bilsland AE, Evans TR, Roffey J, Bennett DC, Narita M, Torrance CJ, Keith WN. Cancer cell senescence: a new frontier in drug development. Drug Discov Today 17: 269-76, 2012

Venugopal B, Evans TR. Late recurrences of renal cell carcinoma at unusual sites: implications for patient management. Clin Adv Hematol Oncol 10: 126-8, 2012

2011
Boss DS, Glen H, Beijnen JH, de Jong D, Wanders J, Evans TR, Schellens JH (2011). Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report. Tumori 97, 109-14.

Leijen S, Soetekouw PM, Evans TRJ, Nicolson M, Schellens JH, Learoyd M, Grinsted L, Zazulina V, Pwint T, Middleton M. A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemother Pharmacol doi: 10.1007/s00280-011-1732-72011, published online 28 Sep 2011

Mitchell CL, O'Connor JP, Roberts C, Watson Y, Jackson A, Cheung S, Evans J, Spicer J, Harris A, Kelly C, Rudman S, Middleton M, Fielding A, Tessier J, Young H, Parker GJ, Jayson GC. A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemother Pharmacol 2011; 68: 631-41

O'Bryant CL, Haluska P, Rosen L, Ramanathan RK, Venugopal B, Leong S, Boinpally R, Franke A, Witt K, Evans J, Belani C, Gail Eckhardt S, Ramalingam S. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemother Pharmacol doi 10.1007/s00280-011-1733-6, published online 22 Sep 2011

Venugopal B, Evans TR (2011). Developing histone deacetylase inhibitors as anti-cancer therapeutics. Curr Med Chem. 18, 1658-71.

Venugopal B, Evans TRJ. Gemcitabine Elaidate. Drugs of the Future 2011; 36: 427-32

2010
Ahmad I, Morton JP, Singh LB, Radulescu SM, Ridgway RA, Patel S, Woodgett J, Winton DJ, Taketo MM, Wu XR, Leung HY, Sansom OJ (2010). beta-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene 30, 178-89.

Ashton GH, Morton JP, Myant K, Phesse TJ, Ridgway RA, Marsh V, Wilkins JA, Athineos D, Muncan V, Kemp R, Neufeld K, Clevers H, Brunton V, Winton DJ, Wang X, Sears RC, Clarke AR, Frame MC, Sansom OJ (2010). Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling. Dev Cell 19, 259-69.

Doyle B, Morton JP, Delaney DW, Ridgway RA, Wilkins JA, Sansom OJ (2010). p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J Pathol. 222, 129-37.

Lolkema MP, Arkenau H-T, Harrington K, Roxburgh P, Morrison R, Roulstone V, Coffey M, Mettinger K, Gill G, Evans TRJ, de Bono JS (2010). A phase-I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res. 17, 581-8.

Mansi JL, Yellowlees A, Lipscombe J, Earl HM, Cameron DA, Coleman RE, Perren T, Gallagher CJ, Quigley M, Crown J, Jones AL, Highley M, Leonard RC, Evans TR (2010). Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study. Breast Cancer Res Treat. 122, 787-94.

Mitchell CL, O'Connor JP, Roberts C, Watson Y, Jackson A, Cheung S, Evans J, Spicer J, Harris A, Kelly C, Rudman S, Middleton M, Fielding A, Tessier J, Young H, Parker GJ, Jayson GC (2010). A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemother Pharmacol. 2010 Dec 1. [Epub ahead of print]

Morton JP, Jamieson NB, Karim SA, Athineos D, Ridgway RA, Nixon C, McKay CJ, Carter R, Brunton VG, Frame MC, Ashworth A, Oien KA, Evans TR, Sansom OJ (2010). LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology 139, 586-97.

Morton JP, Karim SA, Graham K, Timpson P, Jamieson N, Athineos D, Doyle B, McKay C, Heung MY, Oien KA, Frame MC, Evans TR, Sansom OJ, Brunton VG (2010). Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology 139, 292-303.

Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, Frame MC, Evans TRJ, Sansom OJ (2010). Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 107, 246-51.

Steele NL, Plumb JA, Vidal L, Tjornelund J, Knoblauch P, Buhl-Jensen P, Molife R, Brown R, de Bono JS, Evans TR (2010). Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemother Pharmacol. 67, 1273-9.

Brown J, Evans TRJ (2010). In: Medical Radiology - New Concepts in Diagnosis and Therapy of Pancreatic Adenocarcinoma (ed: Laghi A) pp137-46. Springer, Heidelberg.

Evans TRJ (2010). Upper Gastrointestinal Cancer. In: Oxford Handbook of Oncology, 3rd Edition (eds: Cassidy J, Bissett D, Spence RAJ, Payne M) pp333-53. Oxford University Press, Oxford.

Morton JP, Sansom OJ, Evans TRJ (2010). Pancreatic Cancer Therapy – Lessons from Mouse Models. Gastrointestinal Cancer Abstracts 29, 2-7.

2009
Demetri GD, Lo Russo P, Macpherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR (2009). Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors. Clin Cancer Res. 15, 6232-40.

Graham JS, Falk S, Samuel LM, Cendros JM, Evans TRJ (2009). A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy. Cancer Chemotherapy & Pharmacology 63, 945-52.

Scott LC, Yao JC, Benson AB, 3rd,Thomas AL, Falk S, Mena RR, Picus J,Wright J, Mulcahy MF, Ajani JA, Evans TRJ (2009). A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemotherapy & Pharmacology 63, 363-70.

Venugopal B, Evans TR (2009). Coexistent malignant melanoma and renal cell carcinoma. Tumori 95, 518-20.

Braidwood L, Dunn PD, Hardy S, Evans TR, Brown SM (2009). Antitumor Activity of a Selectively Replication Competent Herpes Simplex Virus (HSV) with Enzyme Prodrug Therapy. Anticancer Res. 29, 2159-66.

Koutras AK, Giannopoulou E, Antonacopoulou A, Evans TRJ, Kalofonos HP (2009). Antiproliferative effect of exemestane in lung cancer cells. Molecular Cancer 8, 109.

Scott LC, Evans TR, Cassidy J, Harden S, Paul J, Ullah R, O'Brien V, Brown R (2009). Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. Br J Cancer 101, 410-7.

Harrington J, Evans TRJ (2009). Recent Advances in the Systemic Therapy of Cancer. Journal of the Royal College of Physicians of Edinburgh 39, 134-7.

Macpherson IRJ, Evans TRJ (2009). New approaches in the management of advanced breast cancer – role of combination treatment with liposomal doxorubicin. Breast Cancer – Targets and Therapy 1, 1-18.

2008
Morton JP, Klimstra DS, Mongeau ME, Lewis BC (2008). Trp53 deletion stimulates the formation of metastatic pancreatic tumors. Am J Path. 172, 1081-7.

Plummer R, Jones R, Middleton M,Wilson R, Evans J, Olsen A, Curtin N, Boddy A, McHugh P, Newell D, Harris A, Johnston P, Steinfeldt H, Dewji R,Wang D, Robson L, Calvert H (2008). Phase I study of the poly(ADP-Ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumours. Clin Cancer Res. 23, 7917-23.

Sarker D, Molife R, Evans TRJ, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R, Fox JA, Heise C, Louie S,Aziz N, Garzon F, Michelson G, Judson IR, Jadayel D, Braendle E, de Bono JS (2008). A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res. 14, 2075-81.

Steele NL, Plumb JA,Vidal L,Tjornelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TRJ, DeBono JS (2008). A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 14, 804-10.

Evans J, Chitnis MM,Talbot DC (2008). Principles of chemotherapy and drug development. In P. Price, K. Sikora and T. Illidge, ed. Treatment of cancer. London: Hodder Arnold 2008; 75-111

Koutras AK, Mastronikolis NS, Evans TRJ, Papadeas ES, Makatsoris T, Kalofonos HP (2008). Irreversible ototoxicity associated with the use of erlotinib in a patient with pancreatic cancer. Acta Oncologica 47, 1171-73.

Koutras AK, Evans TRJ (2008). The epidermal growth factor receptor family in breast cancer. Onco Targets & Therapy 1, 5-19.

Oien KA, Evans TRJ (2008). Raising the profile of cancer of unknown primary. J Clin Oncol. 26, 4373-75.

Roxburgh P, Evans TRJ (2008). Systemic therapy of hepatocellular carcinoma: Are we making progress? Advances in Therapy 25, 1089-104.

Holmes WM, Maclellan S, Condon B, Dufes C, Evans TRJ, Uchegbu IF, Schätzlein AG (2008). High-resolution 3D isotropic MR imaging of mouse flank tumours obtained in vivo with solenoid RF micro-coil. Physics in Medicine & Biology 53, 505-13.

Jones RJ, Hawkins RE, Eatock MM, Ferry DR, Eskens FA, Wilke H, Evans TRJ (2008). A phase II open label study of DHApaclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemotherapy & Pharmacology 61, 435-41.

Lindsay CR, Evans TRJ (2008). Targeting insulin growth factor receptors: a potential novel anti-cancer therapy. Biologics: Targets & Therapy 2, 855-64.

Associate Scientist: Jen Morton

Scientific Officer: Saadia Karim

Research Associate: Amy Au (Pancreatic Cancer Research Fund)